Crestor reduces heart disease by 50 percent

The latest study on statin drugs boasts that the medication, Crestor, reduces heart attacks by 50 percent.

As several have pointed out, this study called "The Jupiter Study" was financed by the manufacturer of Crestor and in the FenPhen trials, Wyeth petitioned to not have to testify in court about their removal of negative results from the FenPhen studies because the removal of negative study results was "common practice" in the pharmaceutical field. Their petition was granted and this aspect was never saw the light in court.

Additionally, several (including Dr Mercola and Dr Linda Bacon, in "HEALTH AT EVERY SIZE") have cited studies which suggest that the corporation which finances a study is likely to find positive results FROM the study for THEIR product. In the post graduate class about de-coding studies, students were taught that the first step is to ask who is financing the study.

Supposedly according to Dr Mercola, in the group of 17,000 participants in the Jupiter study, less than 2 perent had a cardiovascular incident (these were generally healthy people with high C Reactive protein levels). That is, 2 percent in the control group and 1 percent in the Crestor group.

True that can be expressed as a 50 percent less chance of heart disease in those on Crestor but in reality the percentage is only 1 percent less which isn't exactly astounding.

It is enough to create a splashy headline though and sell lots of Crestor, even to people of normal cholesterol levels. (As if they are not selling enough already - I guess never too much in sales is the rule here). :)

But for a 1 percent less chance of heart attack is it really worth it to deal with the side effects of Crestor which include (according to Dr Mercola):

• Anemia
• Acidosis
• Frequent fevers
• Cataracts
• Muscle pain and weakness
• An increase in cancer risk

But many will rush out and ask their doctors for Crestor and the cha-ching of the money coming in, will be heard 'round the world. Another successful endeavor by the pharmaceuticals...